Russia has developed an mRNA vaccine against cancer and will distribute it to patients free of charge, Director General of the Research Center for Radiology of the Russian Health Ministry Andrey Kaprin told Radio Rossiya.
The vaccine, developed in collaboration with several research centers, is expected to hit the market in early 2025.
Earlier, Director of the Gamaleya National Research Center for Epidemiology and Microbiology Alexander Gintsburg told TASS that preclinical trials of the cancer vaccine showed that the vaccine suppresses tumor growth and potential metastasis.
"In the preclinical phase, we saw that the tumor (melanoma) disappeared, and not only the tumor but also the metastases disappeared. I do not exclude the possibility that we will have stage 4 cancer patients using this vaccine," RIA Novosti quoted Mr. Ginzburg.
According to him, the Gamaleya Center, the National Center for Medical Oncology Research, along with several institutes and groups of scientists, have begun testing the effects of the vaccine on several other types of cancer, such as lung, kidney and pancreatic cancer.
Previously, Mr. Ginzburg stated that cancer vaccines are produced individually for each patient. Artificial intelligence (AI) supports the vaccine development process, creating a drug regimen after analyzing tumor parameters. It can take only 7 days to create a drug.
Andrey Kaprin confirmed that clinical trials for the cancer vaccine have been completed and will be distributed free of charge to patients.
